• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

  • image

    Developing precision therapies

    for type 1 diabetes

  • image

    Intralymphatic immunotherapy

    with Diamyd®

Anmälan om deltagande vid extra bolagsstämma

Aktieägarna i Diamyd Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 26 juni 2023 kl.10:00.


Company Presentation

 April 13, 2023

Thanks to JDRF's very large network, strong brand and financial support, the collaboration significantly strengthens our preparations for market and further accelerates patient recruitment for the Phase 3 trial DIAGNODE-3.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 2 22/23


 Dates for financial information and other events
June 2 − June 8, 2023
BIO International Convention
June 13, 2023
Aktiespararnas Småbolagsdagar
June 23 − June 26, 2023
ADA 83rd Scientific Sessions
June 26, 2023
Extra General Meeting
June 28, 2023
Quarterly Report III
Quarterly Report 3 2022/2023
October 11, 2023
Year-end report
Year-end report 2022/2023


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research